title: Designing of promiscuous inhibitors against pancreatic cancer cell lines.
abstract: Pancreatic cancer remains the most devastating disease with worst prognosis. There is a pressing need to accelerate the drug discovery process to identify new effective drug candidates against pancreatic cancer. We have developed QSAR models for predicting promiscuous inhibitors using the pharmacological data. Our models achieved maximum Pearson correlation coefficient of 0.86, when evaluated on 10-fold cross-validation. Our models have also successfully validated the drug-to-oncogene relationship and further we used these models to screen FDA approved drugs and tested them in vitro. We have integrated these models in a webserver named as DiPCell, which will be useful for screening and designing novel promiscuous drug molecules. We have also identified the most and least effective drugs for pancreatic cancer cell lines. On the other side, we have identified resistant pancreatic cancer cell lines, which need investigative scanner on them to put light on resistant mechanism in pancreatic cancer.
authors.affiliation: 1] Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh-160036, India [2].
authors.forename: Rahul
authors.initials: R
authors.lastname: Kumar
authors.affiliation: 1] Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh-160036, India [2].
authors.forename: Kumardeep
authors.initials: K
authors.lastname: Chaudhary
authors.affiliation: 1] Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh-160036, India [2] Centre for Microbial Biotechnology, Panjab University, Chandigarh-160014 [3].
authors.forename: Deepak
authors.initials: D
authors.lastname: Singla
authors.affiliation: Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh-160036, India.
authors.forename: Ankur
authors.initials: A
authors.lastname: Gautam
authors.affiliation: Bioinformatics Centre, CSIR-Institute of Microbial Technology, Chandigarh-160036, India.
authors.forename: Gajendra P S
authors.initials: GP
authors.lastname: Raghava
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D020407:Internet; D008956:Models, Chemical; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology; D021281:Quantitative Structure-Activity Relationship; D014584:User-Computer Interface
chemical_list: D000970:Antineoplastic Agents
references.citation: Nature. 2013 Dec 19;504(7480):389-93
references.pmid: 24284626
references.citation: Nature. 2012 Mar 28;483(7391):603-7
references.pmid: 22460905
references.citation: Surg Oncol. 1997 Nov;6(3):157-69
references.pmid: 9576631
references.citation: Aliment Pharmacol Ther. 2003 Dec;18(11-12):1049-69
references.pmid: 14653825
references.citation: Mol Syst Biol. 2009;5:310
references.pmid: 19888205
references.citation: Bioinformatics. 2004 Oct 12;20(15):2479-81
references.pmid: 15073010
references.citation: Expert Opin Ther Targets. 2011 Jul;15(7):817-28
references.pmid: 21391891
references.citation: Cancer Treat Rev. 2009 Aug;35(5):431-6
references.pmid: 19328630
references.citation: Mol Cancer Ther. 2010 Feb;9(2):257-67
references.pmid: 20124458
references.citation: Nat Rev Drug Discov. 2004 Aug;3(8):673-83
references.pmid: 15286734
references.citation: Curr Genomics. 2008 Sep;9(6):394-408
references.pmid: 19506729
references.citation: IEEE Trans Neural Netw. 2006 Jul;17(4):1039-49
references.pmid: 16856665
references.citation: APMIS. 2007 Oct;115(10):1039-59
references.pmid: 18042143
references.citation: Nature. 2007 Aug 9;448(7154):645-6
references.pmid: 17687303
references.citation: Sci Rep. 2013;3:1445
references.pmid: 23486013
references.citation: Nat Rev Drug Discov. 2013 Dec;12(12):948-62
references.pmid: 24287782
references.citation: Expert Rev Anticancer Ther. 2010 Oct;10(10):1647-61
references.pmid: 20942635
references.citation: Nat Med. 2011 Mar;17(3):330-9
references.pmid: 21386836
references.citation: Cancer Res. 2008 Mar 15;68(6):1970-8
references.pmid: 18339879
references.citation: J Cheminform. 2011 Oct 07;3:33
references.pmid: 21982300
references.citation: Oncol Rep. 2010 May;23(5):1183-92
references.pmid: 20372829
references.citation: Am J Epidemiol. 2007 Feb 1;165(3):334-43
references.pmid: 17082497
references.citation: Cancer Cell. 2006 Dec;10(6):515-27
references.pmid: 17157791
references.citation: Sci Rep. 2014 Feb 26;4:4197
references.pmid: 24569397
references.citation: Nat Med. 2012 Jun;18(6):956-60
references.pmid: 22610278
references.citation: Cancer Res. 2012 Jul 15;72(14):3499-511
references.pmid: 22802077
references.citation: Nature. 2012 Mar 28;483(7391):570-5
references.pmid: 22460902
references.citation: N Engl J Med. 2010 Apr 29;362(17):1605-17
references.pmid: 20427809
references.citation: Acta Gastroenterol Belg. 1989 Sep-Dec;52(5-6):458-66
references.pmid: 2486016
references.citation: Cancer Res. 2011 Aug 15;71(16):5535-45
references.pmid: 21705440